{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T02:30:19Z","timestamp":1786501819110,"version":"build-2736575974"},"reference-count":106,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.prp.2026.156615","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:34:44Z","timestamp":1783524884000},"page":"156615","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Ethanolamine phosphate phospholyase in NAFLD: Emerging mechanisms, pathways, and therapeutic opportunities"],"prefix":"10.1016","volume":"286","author":[{"given":"Jiaqi","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijing","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.prp.2026.156615_bib1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.prp.2026.156615_bib2","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","article-title":"Changing epidemiology, global trends and implications for outcomes of NAFLD","volume":"79","author":"Wong","year":"2023","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.prp.2026.156615_bib3","doi-asserted-by":"crossref","DOI":"10.1111\/eci.70132","article-title":"Metabolic dysfunction-associated steatotic liver disease, insulin resistance and hepatocellular carcinoma: a deadly triad","volume":"56","author":"Caturano","year":"2026","journal-title":"Eur. J. Clin. Investig."},{"issue":"6","key":"10.1016\/j.prp.2026.156615_bib4","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jhep.2023.08.008","article-title":"Progression of non-alcoholic fatty liver disease and long-term outcomes: a nationwide paired liver biopsy cohort study[J\/OL]","volume":"79","author":"Simon","year":"2023","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.prp.2026.156615_bib5","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3390\/biology13050352","article-title":"Associations between \u201ccancer risk\u201d, \u201cinflammation\u201d and \u201cmetabolic syndrome\u201d: a scoping review","volume":"13","author":"Vitale","year":"2024","journal-title":"Biology"},{"issue":"1","key":"10.1016\/j.prp.2026.156615_bib6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12986-023-00748-x","article-title":"Pharmacotherapies of NAFLD: updated opportunities based on metabolic intervention","volume":"20","author":"Shao","year":"2023","journal-title":"Nutr. Metab."},{"issue":"13","key":"10.1016\/j.prp.2026.156615_bib7","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.3390\/ijms26136518","article-title":"Pharmacological treatment of MASLD: contemporary treatment and future perspectives","volume":"26","author":"Drygalski","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.prp.2026.156615_bib8","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1002\/jcp.30993","article-title":"ETNPPL modulates hyperinsulinemia-induced insulin resistance through the SIK1\/ROS-mediated inactivation of the PI3K\/AKT signaling pathway in hepatocytes","volume":"238","author":"Chen","year":"2023","journal-title":"J. Cell. Physiol."},{"issue":"1","key":"10.1016\/j.prp.2026.156615_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100830","article-title":"The role of ethanolamine phosphate phospholyase in regulation of astrocyte lipid homeostasis","volume":"297","author":"White","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.prp.2026.156615_bib10","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.freeradbiomed.2023.02.017","article-title":"ETNPPL impairs autophagy through regulation of the ARG2-ROS signaling axis, contributing to palmitic acid-induced hepatic insulin resistance","volume":"199","author":"Wang","year":"2023","journal-title":"Free. Radic. Biol. Med."},{"issue":"5","key":"10.1016\/j.prp.2026.156615_bib11","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.prp.2026.156615_bib12","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/MOG.0000000000000927","article-title":"Advances in the genetics of nonalcoholic fatty liver disease","volume":"39","author":"Ajmera","year":"2023","journal-title":"Curr. Opin. Gastroenterol."},{"issue":"6","key":"10.1016\/j.prp.2026.156615_bib13","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1074\/jbc.M112.434183","article-title":"Phosphatidylethanolamine deficiency in Mammalian mitochondria impairs oxidative phosphorylation and alters mitochondrial morphology","volume":"288","author":"Tasseva","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"9733","key":"10.1016\/j.prp.2026.156615_bib14","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/S0140-6736(10)60408-4","article-title":"Lipid-induced insulin resistance: unravelling the mechanism","volume":"375","author":"Samuel","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.prp.2026.156615_bib15","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cld.2004.04.004","article-title":"The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease","volume":"8","author":"Mccullough","year":"2004","journal-title":"Clin. Liver Dis."},{"issue":"4","key":"10.1016\/j.prp.2026.156615_bib16","article-title":"Down-regulation of different post-receptor signal transduction pathways by chronic insulin stimulation","author":"Yuan","year":"2003","journal-title":"Chin. J. Endocrinol. Metab."},{"issue":"24","key":"10.1016\/j.prp.2026.156615_bib17","doi-asserted-by":"crossref","first-page":"9682","DOI":"10.3390\/ijms21249682","article-title":"Cell Death in Liver Diseases: A Review","volume":"21","author":"Shojaie","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2026.156615_bib18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/978-981-10-8684-7_10","article-title":"Autophagy, NAFLD and NAFLD-Related HCC","volume":"1061","author":"Wu","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.prp.2026.156615_bib19","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/480508","article-title":"The role of autophagy in liver diseases: mechanisms and potential therapeutic targets","volume":"2015","author":"Cursio","year":"2015","journal-title":"BioMed. Res. Int."},{"issue":"4","key":"10.1016\/j.prp.2026.156615_bib20","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCRESAHA.115.304262","article-title":"OxLDL triggers retrograde translocation of arginase2 in aortic endothelial cells via ROCK and mitochondrial processing peptidase","volume":"115","author":"Pandey","year":"2014","journal-title":"Circ. Res."},{"issue":"6","key":"10.1016\/j.prp.2026.156615_bib21","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.tips.2015.03.006","article-title":"Arginase: an old enzyme with new tricks","volume":"36","author":"Caldwell","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.prp.2026.156615_bib22","article-title":"Uncoupling of endothelial NO synthase in atherosclerosis and vascular disease","volume":"13","author":"H","year":"2013","journal-title":"Curr. Opin. Pharmacol."},{"issue":"3","key":"10.1016\/j.prp.2026.156615_bib23","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.kint.2020.03.032","article-title":"Arginase 2 is a mediator of ischemia-reperfusion injury in the kidney through regulation of nitrosative stress","volume":"98","author":"Hara","year":"2020","journal-title":"Kidney Int."},{"issue":"7","key":"10.1016\/j.prp.2026.156615_bib24","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1080\/15548627.2017.1320467","article-title":"Autophagy impairment mediated by S-nitrosation of ATG4B leads to neurotoxicity in response to hyperglycemia","volume":"13","author":"Li","year":"2017","journal-title":"Autophagy"},{"issue":"21","key":"10.1016\/j.prp.2026.156615_bib25","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1111\/febs.13736","article-title":"To eat, or NOt to eat: S-nitrosylation signaling in autophagy","volume":"283","author":"Montagna","year":"2016","journal-title":"FEBS J."},{"issue":"18","key":"10.1016\/j.prp.2026.156615_bib26","article-title":"The emerging role of ethanolamine phosphate phospholyase in regulating hepatic phosphatidylethanolamine and plasma lipoprotein metabolism in mice","volume":"38","author":"Elmihi K","year":"2024","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"issue":"4","key":"10.1016\/j.prp.2026.156615_bib27","article-title":"Alterations in phosphatidylethanolamine metabolism impacts hepatocellular lipid storage, energy homeostasis, and proliferation","volume":"1870","author":"Holdaway","year":"2025","journal-title":"Biochim. Et. Biophys. Acta Mol. Cell. Biol. Lipids"},{"key":"10.1016\/j.prp.2026.156615_bib28","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/4829180","article-title":"Ethanolamine and Phosphatidylethanolamine: Partners in Health and Disease","volume":"2017","author":"Patel","year":"2017","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"23","key":"10.1016\/j.prp.2026.156615_bib29","doi-asserted-by":"crossref","first-page":"13107","DOI":"10.3390\/ijms252313107","article-title":"The Role of ETNPPL in Dopaminergic Neuron Stability: Insights from Neuromelanin-Associated Protein Expression in Parkinson\u2019s Disease","volume":"25","author":"Schillaci","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"39","key":"10.1016\/j.prp.2026.156615_bib30","doi-asserted-by":"crossref","first-page":"14205","DOI":"10.3748\/wjg.v20.i39.14205","article-title":"Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease","volume":"20","author":"Paradies","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"7","key":"10.1016\/j.prp.2026.156615_bib31","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.freeradbiomed.2007.12.029","article-title":"Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases","volume":"44","author":"Mantena","year":"2008","journal-title":"Free. Radic. Biol. & Med."},{"issue":"11","key":"10.1016\/j.prp.2026.156615_bib32","doi-asserted-by":"crossref","first-page":"854","DOI":"10.3109\/10715762.2013.830717","article-title":"Mitochondrial dysfunction in non-alcoholic fatty liver disease and insulin resistance: cause or consequence?","volume":"47","author":"Garc\u00eda-Ruiz","year":"2013","journal-title":"Free. Radic. Res."},{"issue":"4","key":"10.1016\/j.prp.2026.156615_bib33","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/hep.26226","article-title":"Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease","volume":"58","author":"Begriche","year":"2013","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.prp.2026.156615_bib34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.freeradbiomed.2011.10.003","article-title":"Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis[J\/OL]","volume":"52","author":"Rolo","year":"2012","journal-title":"Free. Radic. Biol. & Med."},{"issue":"4","key":"10.1016\/j.prp.2026.156615_bib35","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/01926230701320337","article-title":"Apoptosis: a review of programmed cell death","volume":"35","author":"Elmore","year":"2007","journal-title":"Toxicol. Pathol."},{"issue":"6805","key":"10.1016\/j.prp.2026.156615_bib36","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/35037722","article-title":"Corpse clearance defines the meaning of cell death","volume":"407","author":"Savill","year":"2000","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.prp.2026.156615_bib37","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.4049\/jimmunol.171.9.4672","article-title":"Silent cleanup of very early apoptotic cells by macrophages","volume":"171","author":"Kurosaka","year":"2003","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.prp.2026.156615_bib38","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.cmet.2011.03.009","article-title":"AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice","volume":"13","author":"Li","year":"2011","journal-title":"Cell. Metab."},{"issue":"2","key":"10.1016\/j.prp.2026.156615_bib39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/livers6020017","article-title":"TM6SF2 in hepatic lipid metabolism and chronic liver disease","volume":"6","author":"Al-Nakeb","year":"2026","journal-title":"Livers"},{"key":"10.1016\/j.prp.2026.156615_bib40","article-title":"An overview of ferroptosis in non-alcoholic fatty liver disease","volume":"153","author":"Wang","year":"2022","journal-title":"Biomed. & Pharmacother. = Biomedecine & Pharmacother."},{"key":"10.1016\/j.prp.2026.156615_bib41","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.freeradbiomed.2020.02.027","article-title":"Lipid peroxidation and ferroptosis: The role of GSH and GPx4","volume":"152","author":"Ursini","year":"2020","journal-title":"Free. Radic. Biol. & Med."},{"issue":"6","key":"10.1016\/j.prp.2026.156615_bib42","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41580-024-00703-5","article-title":"The cell biology of ferroptosis","volume":"25","author":"Dixon","year":"2024","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"issue":"1","key":"10.1016\/j.prp.2026.156615_bib43","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41420-021-00579-w","article-title":"Ferroptosis: a cell death connecting oxidative stress, inflammation and cardiovascular diseases","volume":"7","author":"Yu","year":"2021","journal-title":"Cell. Death Discov."},{"issue":"3","key":"10.1016\/j.prp.2026.156615_bib44","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.tcb.2015.10.014","article-title":"Ferroptosis: Death by Lipid Peroxidation","volume":"26","author":"Yang","year":"2016","journal-title":"Trends Cell. Biol."},{"issue":"10","key":"10.1016\/j.prp.2026.156615_bib45","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1080\/15548627.2023.2218764","article-title":"GPX4 in cell death, autophagy, and disease","volume":"19","author":"Xie","year":"2023","journal-title":"Autophagy"},{"key":"10.1016\/j.prp.2026.156615_bib46","article-title":"GPX4, ferroptosis, and diseases","volume":"174","author":"Zhang","year":"2024","journal-title":"Biomed. & Pharmacother. = Biomedecine & Pharmacother."},{"issue":"3","key":"10.1016\/j.prp.2026.156615_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188890","article-title":"GPX4: The hub of lipid oxidation, ferroptosis, disease and treatment","volume":"1878","author":"Liu","year":"2023","journal-title":"Biochim. Et. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.prp.2026.156615_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2026.151608","article-title":"Ethanolamine phosphate phospholyase drives non-alcoholic fatty liver disease via hepatocyte ferroptosis and ferroptosis-mediated macrophage reprogramming","volume":"357","author":"Gui","year":"2026","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.prp.2026.156615_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2022.110550","article-title":"The role of acetaldehyde dehydrogenase 2 in the pathogenesis of liver diseases","volume":"102","author":"Wu","year":"2023","journal-title":"Cell. Signal."},{"issue":"8","key":"10.1016\/j.prp.2026.156615_bib50","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2022112304","article-title":"p53 protects against alcoholic fatty liver disease via ALDH2 inhibition","volume":"42","author":"Yao","year":"2023","journal-title":"EMBO J."},{"key":"10.1016\/j.prp.2026.156615_bib51","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.freeradbiomed.2023.12.017","article-title":"ALDH2 deficiency exacerbates MCD-diet induced MASLD by modulating bile acid metabolism","volume":"212","author":"Luo","year":"2024","journal-title":"Free. Radic. Biol. & Med."},{"issue":"2","key":"10.1016\/j.prp.2026.156615_bib52","doi-asserted-by":"crossref","first-page":"231","DOI":"10.5114\/ceji.2018.77395","article-title":"Changes in the immune system - the key to diagnostics and therapy of patients with non-alcoholic fatty liver disease","volume":"43","author":"Kosmalski","year":"2018","journal-title":"Cent. -Eur. J. Immunol."},{"issue":"21","key":"10.1016\/j.prp.2026.156615_bib53","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012575","article-title":"TRAF1 Exacerbates Myocardial Ischemia Reperfusion Injury via ASK1-JNK\/p38 Signaling","volume":"8","author":"Xu","year":"2019","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"10.1016\/j.prp.2026.156615_bib54","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bbrc.2019.01.041","article-title":"TRAF1 meditates lipopolysaccharide-induced acute lung injury by up regulating JNK activation","volume":"511","author":"Bin","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.prp.2026.156615_bib55","article-title":"Tetrahydrocurcumin improves lipopolysaccharide-induced myocardial dysfunction by inhibiting oxidative stress and inflammation via JNK\/ERK signaling pathway regulation","volume":"104","author":"Zhu","year":"2022","journal-title":"Phytomedicine Int. J. Phytother. Phytopharm."},{"issue":"1","key":"10.1016\/j.prp.2026.156615_bib56","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s12035-023-03561-y","article-title":"Role of brain liver X receptor in parkinson\u2019s disease: hidden treasure and emerging opportunities","volume":"61","author":"Alnaaim","year":"2024","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.prp.2026.156615_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2020.06.010","article-title":"STAT3: a key regulator in liver fibrosis","volume":"21","author":"Zhao","year":"2021","journal-title":"Ann. Hepatol."},{"issue":"12","key":"10.1016\/j.prp.2026.156615_bib58","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.1039\/C8FO01227J","article-title":"Blueberry, combined with probiotics, alleviates non-alcoholic fatty liver disease via IL-22-mediated JAK1\/STAT3\/BAX signaling","volume":"9","author":"Zhu","year":"2018","journal-title":"Food & Funct."},{"issue":"12","key":"10.1016\/j.prp.2026.156615_bib59","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.4161\/15548627.2014.981789","article-title":"ARG2 impairs endothelial autophagy through regulation of MTOR and PRKAA\/AMPK signaling in advanced atherosclerosis","volume":"10","author":"Xiong","year":"2014","journal-title":"Autophagy"},{"issue":"5","key":"10.1016\/j.prp.2026.156615_bib60","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1257","article-title":"Macrophage metabolic reprogramming and atherosclerotic plaque microenvironment: Fostering each other?","volume":"13","author":"Xiao","year":"2023","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.prp.2026.156615_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.746151","article-title":"Meta-Inflammation and Metabolic Reprogramming of Macrophages in Diabetes and Obesity: The Importance of Metabolites","volume":"12","author":"Russo","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.prp.2026.156615_bib62","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1186\/s40001-024-02069-y","article-title":"Metabolic reprogramming of macrophages in the context of type 2 diabetes","volume":"29","author":"Witcoski Junior","year":"2024","journal-title":"Eur. J. Med. Res."},{"issue":"4","key":"10.1016\/j.prp.2026.156615_bib63","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.smim.2015.09.001","article-title":"Contribution of metabolic reprogramming to macrophage plasticity and function","volume":"27","author":"El Kasmi","year":"2015","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.prp.2026.156615_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173090","article-title":"Macrophage M1\/M2 polarization","volume":"877","author":"Yunna","year":"2020","journal-title":"Eur. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.prp.2026.156615_bib65","article-title":"Research progress on the regulation of metabolism and pro-inflammation related macrophage polarization","volume":"5","author":"Liu","year":"2018","journal-title":"E-J. Transl. Med."},{"key":"10.1016\/j.prp.2026.156615_bib66","article-title":"The impact of non-coding RNAs on macrophage polarization","volume":"142","author":"Ghafouri-Fard","year":"2021","journal-title":"Biomed. & Pharmacother. = Biomedecine & Pharmacother."},{"issue":"1","key":"10.1016\/j.prp.2026.156615_bib67","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1038\/s41467-021-21617-2","article-title":"Mitochondrial arginase-2 is essential for IL-10 metabolic reprogramming of inflammatory macrophages","volume":"12","author":"Dowling","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2026.156615_bib68","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.omtn.2022.08.004","article-title":"Enhancing arginase 2 expression using target site blockers as a strategy to modulate macrophage phenotype","volume":"29","author":"De Santi","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"1","key":"10.1016\/j.prp.2026.156615_bib69","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41420-023-01749-8","article-title":"Programmed cell death in hepatic fibrosis: current and perspectives","volume":"9","author":"Lu","year":"2023","journal-title":"Cell. Death Discov."},{"issue":"3","key":"10.1016\/j.prp.2026.156615_bib70","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s10620-020-06100-0","article-title":"Fecal Microbiota Transplantation for Chronic Liver Diseases: Current Understanding and Future Direction","volume":"65","author":"Lechner","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.prp.2026.156615_bib71","article-title":"Case report: hyperbilirubinemia in gilbert syndrome attenuates covid-19-induced metabolic disturbances","volume":"8","author":"Al-Kuraishy","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"issue":"5","key":"10.1016\/j.prp.2026.156615_bib72","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/s41418-023-01138-9","article-title":"N6-Methyladenosine-modified circSAV1 triggers ferroptosis in COPD through recruiting YTHDF1 to facilitate the translation of IREB2","volume":"30","author":"Xia","year":"2023","journal-title":"Cell. Death Differ."},{"issue":"1","key":"10.1016\/j.prp.2026.156615_bib73","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s12013-024-01555-8","article-title":"Long non-coding RNAs in non-alcoholic fatty liver disease; friends or foes?","volume":"83","author":"Soltanieh","year":"2025","journal-title":"Cell. Biochem. Biophys."},{"issue":"5","key":"10.1016\/j.prp.2026.156615_bib74","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.gastrohep.2023.09.014","article-title":"Long non-coding RNAs as modulators and therapeutic targets in non-alcoholic fatty liver disease (NAFLD)","volume":"47","author":"Tao","year":"2024","journal-title":"Gastroenterol. Y. Hepatol."},{"issue":"3","key":"10.1016\/j.prp.2026.156615_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2023.102095","article-title":"The function of long non-coding RNA in non-alcoholic fatty liver disease","volume":"47","author":"Cao","year":"2023","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"issue":"7","key":"10.1016\/j.prp.2026.156615_bib76","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/oby.21115","article-title":"CYP2J2 overexpression ameliorates hyperlipidemia via increased fatty acid oxidation mediated by the AMPK pathway","volume":"23","author":"Zhang","year":"2015","journal-title":"Obesity"},{"issue":"2","key":"10.1016\/j.prp.2026.156615_bib77","doi-asserted-by":"crossref","first-page":"E97","DOI":"10.1152\/ajpendo.00366.2014","article-title":"CYP2J2 overexpression attenuates nonalcoholic fatty liver disease induced by high-fat diet in mice","volume":"308","author":"Chen","year":"2015","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"22","key":"10.1016\/j.prp.2026.156615_bib78","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.3390\/nu16223789","article-title":"Quercetin\u2019s potential in MASLD: investigating the role of autophagy and key molecular pathways in liver steatosis and inflammation","volume":"16","author":"Katsaros","year":"2024","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.prp.2026.156615_bib79","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3390\/antiox15050648","article-title":"Lycopene ameliorates metabolic dysfunction-associated steatotic liver disease via PINK1\/parkin-mediated mitophagy activation and apoptosis attenuation","volume":"15","author":"Xu","year":"2026","journal-title":"Antioxidants"},{"key":"10.1016\/j.prp.2026.156615_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2026.121677","article-title":"Miao medicine jinshanxiaoke granules alleviates MASLD via ampk\/ppar-\u03b1 and Pi3k\/akt-mediated restoration of hepatic lipid homeostasis","volume":"366","author":"Wang","year":"2026","journal-title":"J. Ethnopharmacol."},{"issue":"PtA","key":"10.1016\/j.prp.2026.156615_bib81","article-title":"Hu gan tang ameliorates metabolic-associated fatty liver disease by inhibiting ferroptosis through the Nrf2\/GPX4 pathway","volume":"353","author":"Cui","year":"2025","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.prp.2026.156615_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.jnutbio.2025.110098","article-title":"Plant sterol ester of \u03b1-linolenic acid protects against ferroptosis in metabolic dysfunction-associated fatty liver disease via activating the Nrf2 signaling pathway","volume":"147","author":"Han","year":"2026","journal-title":"J. Nutr. Biochem."},{"issue":"PtB","key":"10.1016\/j.prp.2026.156615_bib83","article-title":"Nelumbinis plumula attenuates high-fat-induced inflammation in non-alcoholic fatty liver through the NOX\/NF-\u03baB pathway","volume":"355","author":"Zhao","year":"2026","journal-title":"J. Ethnopharmacol."},{"issue":"7","key":"10.1016\/j.prp.2026.156615_bib84","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.70111","article-title":"Platycodon grandiflorum attenuates non-alcoholic fatty liver disease in rats through regulating inflammatory response via PPAR\u03b3 and TLR4\/NF-\u03baB signaling pathway","volume":"39","author":"Dang","year":"2025","journal-title":"Biomed. Chromatogr. BMC"},{"issue":"5","key":"10.1016\/j.prp.2026.156615_bib85","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-\u03b1 and -\u03b4, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"issue":"9972","key":"10.1016\/j.prp.2026.156615_bib86","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.prp.2026.156615_bib87","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.cmet.2017.07.009","article-title":"Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation","volume":"26","author":"Kim","year":"2017","journal-title":"Cell. Metab."},{"key":"10.1016\/j.prp.2026.156615_bib88","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.chemphyslip.2015.08.018","article-title":"Recent progress in the discovery and development of stearoyl CoA desaturase inhibitors","volume":"197","author":"Uto","year":"2016","journal-title":"Chem. Phys. Lipids"},{"issue":"10","key":"10.1016\/j.prp.2026.156615_bib89","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.prp.2026.156615_bib90","first-page":"953","article-title":"The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis","volume":"35","author":"Barreyro","year":"2015","journal-title":"Liver Int. Off. J. Int. Assoc. Study Liver"},{"issue":"2","key":"10.1016\/j.prp.2026.156615_bib91","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123294","article-title":"ASK1 inhibition reduces cell death and hepatic fibrosis in an Nlrp3 mutant liver injury model","volume":"5","author":"Schuster-Gaul","year":"2020","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.prp.2026.156615_bib92","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ajcnut.2024.05.017","article-title":"Curcumin supplementation alleviates hepatic fat content associated with modulation of gut microbiota-dependent bile acid metabolism in patients with nonalcoholic simple fatty liver disease: a randomized controlled trial","volume":"120","author":"He","year":"2024","journal-title":"Am. J. Clin. Nutr."},{"issue":"9","key":"10.1016\/j.prp.2026.156615_bib93","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.cmet.2023.08.002","article-title":"Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations","volume":"35","author":"Ni","year":"2023","journal-title":"Cell. Metab."},{"issue":"1","key":"10.1016\/j.prp.2026.156615_bib94","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s43162-023-00238-9","article-title":"Effects of metformin on fibroblast growth factor 21 in patients with type 2 diabetes mellitus: faraway but so close","volume":"35","author":"Al-Kuraishy","year":"2023","journal-title":"Egypt. J. Intern. Med."},{"key":"10.1016\/j.prp.2026.156615_bib95","article-title":"Statins and non-alcoholic fatty liver disease: a concise review","volume":"183","author":"Da Silva Pereira","year":"2025","journal-title":"Biomed. & Pharmacother. = Biomedecine & Pharmacother."},{"issue":"10","key":"10.1016\/j.prp.2026.156615_bib96","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41574-019-0242-2","article-title":"Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus","volume":"15","author":"Foretz","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"issue":"21","key":"10.1016\/j.prp.2026.156615_bib97","first-page":"3898","article-title":"Effects of Aerobic Interval Training Combined with Daggliflozin in Elderly Patients with Type 2 Diabetes Mellitus Complicated with Nonalcoholic Fatty Liver Disease","volume":"34","author":"Zhang","year":"2025","journal-title":"HENAN Med. Res"},{"issue":"1","key":"10.1016\/j.prp.2026.156615_bib98","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1038\/s41598-025-85658-z","article-title":"Exploring liraglutide\u2019s mechanism in reducing renal fibrosis: the Fsp1-CoQ10-NAD(P)H pathway","volume":"15","author":"Chen","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2026.156615_bib99","doi-asserted-by":"crossref","first-page":"103468","DOI":"10.1016\/j.redox.2024.103468","article-title":"Liraglutide and GLP-1(9-37) alleviated hepatic ischemia-reperfusion injury by inhibiting ferroptosis via GSK3\u03b2\/Nrf2 pathway and SMAD159\/Hepcidin\/FTH pathway","volume":"79","author":"Lu","year":"2025","journal-title":"Redox Biol"},{"issue":"1","key":"10.1016\/j.prp.2026.156615_bib100","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s10020-023-00721-7","article-title":"Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK\/ACC signaling and inhibiting ferroptosis","volume":"29","author":"Guo","year":"2023","journal-title":"Mol. Med."},{"issue":"3","key":"10.1016\/j.prp.2026.156615_bib101","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/14712598.2026.2642273","article-title":"Nivolumab plus ipilimumab for hepatocellular carcinoma: a game-changer?","volume":"26","author":"Di Marco","year":"2026","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"14","key":"10.1016\/j.prp.2026.156615_bib102","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.2217\/fon-2021-1623","article-title":"Locoregional treatments plus immunotherapy in hepatocellular carcinoma: where do we stand?","volume":"18","author":"Rizzo","year":"2022","journal-title":"Future Oncol."},{"issue":"20","key":"10.1016\/j.prp.2026.156615_bib103","doi-asserted-by":"crossref","first-page":"11091","DOI":"10.3390\/ijms252011091","article-title":"Hepatocellular carcinoma immunotherapy: predictors of response, issues, and challenges","volume":"25","author":"Rizzo","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.prp.2026.156615_bib104","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1186\/s12885-026-15893-8","article-title":"Efficacy and safety of immune-based combinations in metastatic hepatocellular carcinoma: a systematic review and network meta-analysis","volume":"26","author":"De Moura","year":"2026","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.prp.2026.156615_bib105","first-page":"2277","article-title":"Elucidation of the role of \u03b1-lipoic acid and vitamin C in methotrexate-induced hepatoxicity in mice","volume":"27","author":"Al-Kuraishy","year":"2023","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.prp.2026.156615_bib106","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/14712598.2026.2642273","article-title":"Nivolumab plus ipilimumab for hepatocellular carcinoma: a game-changer?","volume":"26","author":"Di Marco","year":"2026","journal-title":"Expert. Opin. Biol. Ther."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826002682?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826002682?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T02:26:50Z","timestamp":1786501610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033826002682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":106,"alternative-id":["S0344033826002682"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2026.156615","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ethanolamine phosphate phospholyase in NAFLD: Emerging mechanisms, pathways, and therapeutic opportunities","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2026.156615","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156615"}}